Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Hehlmann, Ruediger

Springer Nature Switzerland AG

06/2022

273

Mole

Inglês

9783030719159

15 a 20 dias

642

Descrição não disponível.
Cytogenetics of Chronic Myeloid Leukemia (CML).- The Biology and Pathogenesis of Chronic Myeloid Leukaemia.- Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy.- CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors.- Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.- Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.- Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update.- Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death.- A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia.- The Role of Hematopoietic Stem Cell Transplantation in CML.- CML end-phase and blast crisis: implications and management.- The Interferon-alpha Revival in CML.- Managing Pregnancy in Chronic Myeloid Leukemia.- Response-Related Predictors of Survival and of Treatment Free Remission in CML.- Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response.



Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Chronic myeloid leukaemia;BCR-ABL;Tyrosine kinase inhibitors;Philadelphia chromosome;Fertility;Hematopoietic stem cell transplantation;Deep molecular response;Interferon-alpha;Survival;Imatinib resistance;Health economics